Alidol F is commonly used across therapeutic domains involving symptomatic discomfort, including conditions presenting with mild to moderate pain, inflammation and swelling, and systemic fever. It is relevant when supportive symptom management is appropriate in acute episodes, such as those involving headaches, menstrual cramps, and joint stiffness.

“The medication provides supportive relief that generally helps patients cope more steadily with difficult episodes and periods of heightened physical discomfort.”

---

Relief from Acute and Cyclical Pain

Alidol F is applied to ease various acute and recurrent scenarios, including common headaches, muscular aches, and the cramping associated with painful menstrual periods. This support provides comfort, supports the patient during difficult episodes by easing distress, and may assist with maintaining functional stability.

---

Symptomatic Support for Inflammatory Conditions

The medicine is relevant for easing the physical signs of inflammation and pain related to chronic conditions like osteoarthritis and acute presentations such as sprains or localized swelling. Its use supports management of the overall symptom load and supports general well-being during symptomatic periods by easing challenging symptoms related to persistent joint stiffness.

---

Management of Fever and Systemic Illness Discomfort

The medication is commonly used for managing elevated body temperature (fever) and generalized body aches associated with illnesses like the common cold or flu. This offers symptomatic relief that helps patients cope more steadily and may assist with the management of elevated body temperature during symptomatic phases.

---

Quick Fact: Symptom Domain Focus
Primary action	Is used for managing symptoms related to inflammatory or irritative states and systemic imbalance.
Key benefit	May support general comfort and help patients cope more steadily with symptom fluctuations.

Population Eligibility for Alidol F (Ibuprofen)

Official regulatory documents define strict criteria regarding who can and cannot use Alidol F, based on age, specific medical history, and physiological status.

---

Category	Regulatory Status / Restriction
Populations for whom use is allowed	Established for use in adults and adolescents (ge 12 years) under standard labeled conditions, provided no contraindications are present [Source 2.1]. Use is established for children ge 6 months (typically for fever and pain, often using specific liquid or chewable dose forms) [Source 1.3].
Populations for whom use is not recommended	Infants younger than 6 months of age are generally not recommended for standard oral tablet use as safety and efficacy are not established [Source 1.3]. Use in women after 20 weeks of pregnancy is not recommended (avoid unless advised by a healthcare professional) [Source 2.2].
Populations for whom use is contraindicated	Absolute prohibition for patients with a history of hypersensitivity to Ibuprofen, aspirin, or other NSAIDs; active or recurrent peptic ulcer/GI haemorrhage (ge 2 distinct episodes); severe heart failure (NYHA Class IV); severe hepatic failure; severe renal failure; and women in the third trimester of pregnancy (ge 30 weeks gestation) [Source 1.1, 1.3, 3.4].

---

Condition-Based Eligibility Rules

• Cardiovascular Conditions: Use in patients with uncontrolled hypertension, congestive heart failure (NYHA Class II-III), established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease requires careful consideration, and high doses (ge 2,400 mg/day) should be avoided [Source 3.5].
• Organ Impairment: Patients with mild to moderate hepatic impairment or renal impairment require caution; function must be monitored [Source 3.1, 3.4].
• Geriatric Use: Elderly patients (ge 65 years) are a Restricted/Conditional Use population due to an increased risk of adverse reactions, requiring particular caution and monitoring [Source 2.5, 3.1].
• Lactation: The medicine is generally considered compatible with breastfeeding as regulatory data suggests it passes into breast milk in very low concentrations [Source 1.2, 2.5].

The regulatory profile for Alidol F (Ibuprofen) identifies several clinically significant interaction patterns, particularly those affecting bleeding risk and drug clearance.

Contraindicated and High-Risk Combinations

The profile establishes restrictions on co-administration due to the risk of serious adverse events. Co-administration with other nonsteroidal anti-inflammatory drugs (NSAIDs), including COX-2 inhibitors, is formally restricted due to an increased risk of gastrointestinal (GI) bleeding and ulceration. Combining Alidol F with anticoagulants (such as Warfarin) or corticosteroids increases the risk of bleeding due to a pharmacodynamic, additive antiplatelet effect.

Exposure Modification

The medicine affects the plasma concentrations of certain co-administered drugs by reducing their renal clearance. This can lead to elevated plasma levels of substances like Lithium and Methotrexate, as officially documented in labeling, increasing the potential for toxicity of these substances.

Efficacy and Timing Constraints

Ibuprofen can reduce the therapeutic efficacy of some medications. This is observed in combination with anti-hypertensives (including ACE inhibitors and ARBs) and diuretics, whose intended blood pressure-lowering or fluid-reducing effects may be diminished. For patients requiring low-dose Aspirin, official documents suggest a separation of administration time to mitigate potential interference with its antiplatelet effect. Furthermore, consumption of three or more alcoholic drinks per day is officially associated with an increased risk of severe GI bleeding. Elderly patients (age 60 or older) are noted to be at a heightened risk for severe interaction-related complications.

Reversible Inhibition of Cyclooxygenase (COX) Enzymes

The active component of Alidol F, Ibuprofen, functions as a non-selective, reversible inhibitor of both Cyclooxygenase-1 ( COX-1) and Cyclooxygenase-2 ( COX-2) enzymes. This action involves the pharmacologically potent S-enantiomer blocking the active site of both isoenzymes. This molecular interference prevents the conversion of arachidonic acid into prostaglandins and other prostanoid mediators, thereby blocking the critical first step in the arachidonic acid cascade. This biochemical blockade modifies early molecular steps within systemic physiological cascades.

Modulation of Peripheral Signaling and Central Set Point

By reducing the local concentration of prostaglandins, the drug alters the signaling dynamics within peripheral nociceptive pathways. Prostaglandins function to sensitize peripheral nerve fibers and modulate local vascular permeability. The reduction of these mediators causes a lower level of chemical input to peripheral nerve fibers, resulting in decreased sensitization and modulation of vascular responses in local tissues. The mechanism also extends centrally: inhibition of PGE2 synthesis within the hypothalamus prevents the upward shift of the thermal set point induced by pyrogenic signals, engaging a mechanism that permits the stabilization of the thermal set point.

How to Use Alidol F: Official Administration Guidelines

The usage of Alidol F, an Ibuprofen preparation, is governed by structured principles established in regulatory documents, defining how much, how often, and under what conditions the medicine is taken. The official guidance distinguishes between short-term use for acute discomfort and long-term regimens for chronic conditions.

---

Administration Scope

Instruction	Official Guideline
Route of Administration	The medicine is approved for oral administration and is taken as a tablet.
Dosing Schedule	Doses range from 200 mg to 800 mg per unit. The maximum daily dose is typically 1,200 mg for non-prescription use, and up to 3,200 mg for prescription indications in divided doses.
Frequency and Timing	For acute use, the standard frequency is every 4 to 6 hours as needed. For long-term use, dosing is often divided into three or four administrations per day.
Timing in relation to meals	Tablets should be taken with a full glass of water. They may be administered with or after food if gastrointestinal discomfort is a concern, though food may delay the onset of action.

---

Procedural and Population Rules

Instruction	Official Guideline
Special Handling	Patients are instructed not to chew, crush, break, or suck on certain tablet formulations.
Duration of Use	Non-prescription use is restricted to short-term periods, such as up to 10 days for pain. Continuous use is reserved for chronic conditions under prescription.
Dose Adjustment	The lowest effective dose should be used for the shortest duration. The label specifies that the lowest dose possible should be used for older adults and those with mild to moderate renal or hepatic impairment.

The official instructions collectively ensure that the administration of Alidol F adheres to specific quantitative and time-based limits, establishing a standardized protocol for its intake.

Research Evidence / Overview of Studies for Alidol F

Evidence for Use in Acute Pain and Symptom Relief

Research examining Alidol F for acute pain and symptom relief has a foundation of study. This body of evidence primarily includes short-term Randomized Controlled Trials (RCTs) and large-scale meta-analyses that observed the medicine in research contexts involving fluctuating or unstable symptoms. Studies were conducted during periods of increased symptom activity and focused on outcomes related to physical discomfort. Researchers examined populations facing conditions associated with acute or disruptive episodes, such as headache, dental pain after procedures, musculoskeletal injuries, and painful menstrual periods (dysmenorrhea).

Studies report how symptoms evolved in the observed populations, describing patterns of measured pain change, particularly in the immediate hours following administration. The structure of the evidence base across these acute pain research contexts is frequently characterized as High-level.

---

Evidence for Use in Managing Elevated Body Temperature (Fever)

Research exploring how symptoms related to elevated body temperature (fever) change over time relies on a consistent structure of Randomized Clinical Trials (RCTs) and systematic reviews. These studies explored research examining temporary physiological imbalance and were often designed as trials comparing it against other agents. The studies monitored outcomes related to systemic or functional imbalance by measuring the degree of temperature change and the time required to achieve a more normalized temperature.

Evidence indicates that studies report measured changes in elevated body temperature across both adult and pediatric populations. Research exploring temporary physiological imbalance describes patterns of change observed during defined time intervals, focusing on time points up to six hours post-dose.

---

Identified Research Gaps and Remaining Uncertainty

While the research base has a foundation of study for many acute uses, several research limitations exist:

• Long-term effects are not fully established regarding the sustained symptomatic changes, as follow-up durations were limited for some outcome measures.
• Data for certain groups remain insufficient, particularly for patients with unique comorbidities or for comparative evidence against all emerging alternative therapies.
• The findings describe group patterns, not personal outcomes; research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review
2. Label: IBUPROFEN tablet, film coated (FDA DailyMed Monograph)

Common questions about Alidol F (FAQ)

---

Q: How quickly does Alidol F start working after taking it?

A: According to official documentation on its kinetics, the onset of action for Alidol F is generally observed within 20 to 30 minutes after taking the dose. The medicine’s most noticeable effects are described as typically reaching their peak concentration within 1 to 2 hours of administration, which generally correlates with maximum symptom relief.

Q: What is the expected duration of Alidol F's effects?

A: The analgesic or fever-reducing effects of a single dose of Alidol F are commonly described in product information as lasting for a period of four to six hours. This duration aligns with the typical recommended dosing interval for acute use of the medicine.

Q: Does Alidol F cause drowsiness or make you sleepy?

A: Official documentation lists side effects related to the central nervous system, which include reports of sleepiness and fatigue. These effects are generally categorized as less common but are officially associated with the use of the medicine.

Q: Can Alidol F affect my ability to drive or operate machinery?

A: Due to the potential for certain side effects such as dizziness or sleepiness, official labeling suggests that caution should be exercised when engaging in activities that require focus, like driving or operating machinery. This advisory is based on the documented potential adverse reaction profile.

Q: Is Alidol F suitable for use in elderly patients?

A: Regulatory information notes that older adults (age 60 or older) are considered a population at a heightened risk for experiencing adverse effects, including severe complications. For this reason, official guidance documents state that the medicine requires particular caution and monitoring when considered for use in this group, and the lowest effective dose is often emphasized.

Q: If I have kidney problems, can I take Alidol F?

A: Official warnings state that Alidol F is explicitly contraindicated, meaning prohibited, for patients diagnosed with severe renal (kidney) failure. For individuals with mild to moderate kidney impairment, the regulatory information advises that the medicine should be used only with caution and that kidney function should be monitored.

Q: Is it normal to feel a change in appetite while taking Alidol F?

A: Yes, official regulatory documentation lists loss of appetite as one of the documented gastrointestinal side effects associated with the medicine. If this symptom is persistent or concerning, it is consistent with the type of information that a healthcare professional typically needs to assess.

Q: What should I do if a potential interaction is listed for Alidol F and my other medication?

A: Official drug information consistently advises that potential interactions are conditions that require review by a healthcare provider, and consulting a professional is advised before taking the medicine. This is necessary so the risk can be assessed individually, taking into account the person's full medical history.

Q: Does Alidol F affect blood sugar levels?

A: Pharmacovigilance evidence suggests that the medicine is associated with documented reports of hypoglycemia, which means abnormally low blood sugar. This effect is particularly noted in individuals who are also receiving treatment for diabetes.

Q: Are there any serious side effects of Alidol F I should be aware of?

A: Yes, official regulatory warnings highlight the possibility of serious side effects. These include the potential for major gastrointestinal ulceration or bleeding and serious cardiovascular events such as heart attack and stroke, especially when the medicine is used for prolonged periods or in high doses.

Q: Can Alidol F be taken with common vitamins and supplements?

A: Official guidelines emphasize that disclosure of all co-administered substances, including vitamins, herbal remedies, and supplements, is necessary for a complete risk assessment by a healthcare professional. This is because these products are generally not formally tested for their ability to affect the intended action of the medicine.

Q: Is Alidol F known to interact with caffeine?

A: Standard regulatory drug interaction tools typically do not list a known direct interaction between the medicine and caffeine. Official guidance often highlights that consulting a healthcare professional regarding all substances, including caffeine, is key to a thorough safety profile review.

Q: Is Alidol F available in different strengths?

A: Yes, the active ingredient in Alidol F (Ibuprofen) is approved for use and commercially available in a range of strengths. These may include 200 mg, 400 mg, 600 mg, and 800 mg forms, depending on whether it is sold as an over-the-counter or a prescription product.

Q: How long can a person typically stay on Alidol F treatment?

A: For non-prescription (OTC) use, the duration is typically restricted by regulatory guidance to short-term periods, such as no more than a few days for fever or up to ten days for pain. Continuous, long-term use extending beyond these limits is reserved for prescribed chronic conditions and requires ongoing medical supervision.

Q: What is the risk of dependence or addiction with Alidol F?

A: Alidol F is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not generally associated with the risks of physical dependence or addictive behavior. The medicine's pharmacological class is distinct from substances known to have a risk of addiction.

Q: Does Alidol F interact with blood pressure medications?

A: Regulatory information confirms that the medicine can reduce the blood pressure-lowering effect of certain anti-hypertensive drugs. The description of this interaction confirms that healthcare providers must be aware of its potential impact on a patient's treatment regimen.

Q: Are there different brand names for the same medicine as Alidol F?

A: Yes, the active ingredient in Alidol F (Ibuprofen) is a common pharmaceutical compound. It is marketed globally under a large number of different brand names, all of which are listed in official drug databases.

Q: Is Alidol F a prescription-only medicine?

A: The active ingredient in Alidol F is commonly available in two ways. Lower strengths are typically available over-the-counter (OTC) without a prescription, while higher doses or specific formulations are generally restricted to prescription-only use.

Q: What is the difference between Alidol F and regular Alidol?

A: If the 'F' in Alidol F indicates a specialized salt or formulation (for example, ibuprofen sodium), the main difference is typically related to the rate of absorption. Some specialized formulations are described as achieving a therapeutic effect faster than standard ibuprofen.

Q: Is Alidol F considered a drug with a high risk of drug-drug interactions?

A: The official documentation detailing several clinically significant interaction patterns, including high-risk combinations with blood thinners, other NSAIDs, and certain blood pressure medications, indicates that a careful review of all co-administered drugs is necessary.

Q: Does Alidol F have a Black Box Warning in the US?

A: Yes, the official labeling in the US includes mandated Boxed Warnings, which are often referred to as 'Black Box Warnings.' These warnings specifically concern the risks of serious cardiovascular events, such as heart attack and stroke, and serious gastrointestinal events, including bleeding and perforation.

Q: Is Alidol F described as having a long half-life?

A: No, the medicine is described in pharmacokinetic profiles as having a relatively short elimination half-life. This time measurement, which indicates how long it takes for half of the dose to be cleared from the body, is typically in the range of 1.9 to 2.2 hours.

Q: Do I need to store Alidol F in the refrigerator?

A: No, the official storage instructions specify that the medicine must be stored at a controlled room temperature. This is typically defined as being below 25 C or 30 C and does not require refrigeration.

Q: What types of health conditions is Alidol F explicitly not for?

A: Official warnings state that the medicine should not be used by patients with a history of hypersensitivity to the drug, active peptic ulcers, or severe organ failure. This includes specific categories of severe heart failure, severe hepatic (liver) failure, and severe renal (kidney) failure.

Q: Does Alidol F affect sleep patterns?

A: Regulatory documentation notes that side effects related to sleep patterns have been reported. These specific reactions include both sleeplessness (insomnia) and, conversely, sleepiness.

Q: Are there different formulations of Alidol F (e.g., tablet, liquid)?

A: Yes, the active ingredient in Alidol F is commonly available in several official formulations. These include oral tablets, capsules, and liquid suspensions, which allow for use in different age groups and for different administration needs.

Q: Why is it important to tell my doctor about all medicines I take while on Alidol F?

A: It is important because the medicine has known, documented interactions with many prescription drugs, such as blood thinners and certain blood pressure medications. Disclosure is necessary to avoid high-risk combinations and manage the potential for increased serious side effects, like gastrointestinal bleeding.

Q: What happens if Alidol F is taken with dairy products?

A: Official labeling indicates that the medicine may be administered with food or milk if the user experiences stomach upset. This is advised as a measure that may help minimize gastrointestinal discomfort.

Q: What is the official information regarding overdose of Alidol F?

A: Official documents specify the maximum allowable daily dose for the medicine. Exceeding this dose is noted to increase the risk of serious adverse events, including heart attack, stroke, and liver damage. Symptoms of overdose are also described in official regulatory labeling.

Q: Is Alidol F the same as a drug I saw advertised on TV?

A: Alidol F contains the active ingredient Ibuprofen. This is the same medicine found in numerous commonly advertised and well-known brand-name products, as is often noted in authoritative drug databases.

Q: Are there genetic factors that influence how Alidol F works?

A: Authoritative information indicates that genetic variations, particularly in the CYP2C9 gene, can affect how the body metabolizes (breaks down) the medicine. This variability may influence an individual's exposure to the medicine and their risk of experiencing adverse drug reactions.

Q: Is Alidol F recommended for long-term use?

A: Official labeling notes that the risk of serious side effects, such as cardiovascular events, may increase with the duration of use. For this reason, continuous, long-term use is reserved for prescribed conditions only and requires regular medical review and assessment.

How to Store and Dispose of Alidol F?

The official labeling for Alidol F (Ibuprofen) dictates specific storage and handling requirements. The medicine must be stored at a controlled room temperature, specifically below 25 C or 30 C, depending on the formulation. It is mandatory to store the tablets in the original container or carton to protect the product from light and moisture. To ensure household safety, the medicine must always be kept out of the sight and reach of children.

For disposal, the regulatory standard is to use an official drug take-back program. If this is unavailable, the unused or expired tablets should be mixed with an unappealing substance, placed in a sealed container, and discarded in household trash according to government guidance. Disposal via wastewater or flushing is generally not permitted.